Answers are grounded in this paper and cite their sources.
No other cancer therapy target class caused more excitement than the programmed death-1 (PD-1) pathway related. Antibodies against PD-1 and PD-1 ligands represent a therapeutic breakthrough and are the first examples of broadly efficacious and durable cancer immunotherapies. Cancer for the first time seems to have transformed from an often incurable to a "clinically manageable" disease.
No takes yet. Share an insight, caveat, or question.
Dömlingꝉ et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: